Press Releases

NICE-SUGAR Survey

Following the completion of the first survey of glycemic control, the report of the NICE-SUGAR Study in critically ill hospitalized patients determined there was “no difference” in ICU morbidity and mortality among patients randomized to tightly controlled blood glucose compared to moderately controlled blood glucose causes further confusion regarding how to best manage inpatient hyperglycemia.7  Additionally, the release of the ADA/AACE Consensus panel statement8 advised a higher and wider target range for glucose control to avoid hypoglycemia.  This followup survey was distributed to determine how hospitals interpreted this new information, and actions taken in response.  Click Here to View the Survey

1. Van den Berghe G, Wouters P, Weekers F, et al., Intensive Insulin Therapy in Critically Ill Patients.  New England Journal of Medicine 2001; 345(19):1359-1367.

2. Furnary AP, Gao G, Grunkemeier GL, Wu Y, et al., Continuous Insulin Infusion Reduces Mortality in Patients With Diabetes Undergoing Coronary Artery Bypass Grafting.  Journal of Thoracic and Cardiovascular Surgery 2003; 12:1007-1021.

3. Van den Berghe G, Wilmer A, Hermans G et al, Intensive Insulin Therapy in the Medical ICU. New England Journal of Medicine 2006; 354(5):449-461.

4. Umpierrez GE, Isaacs SD, Bazargan N, You X et al.  Hyperglycemia: An Independent Marker of In-Hospital Mortality in Patients with Undiagnosed Diabetes.  Journal of Clinical Endocrinology and Metabolism 2002; 87(3):978-982.

5. Krinsley JS, Effect of an Intensive Glucose Management Protocol on the Mortality of Critically Ill Adult Patients.  Mayo Clinic Proceedings 2004; 79(8)992-1000.

6. Lacherade JD, Jabre P, Bastuji-Garin S, et al., Failure to Achieve Glycemic Control Despite Intensive Insulin Therapy in a Medical ICU: Incidence and Influence on ICU Mortality.  Intensive Care Medicine 2007; 33(5):814-21.

7. The NICE-SUGAR Investigators. Intensive versus conventional glucose control in critically ill patients. The New England Journal of Medicine. March 2009; 360(13):1283-1297.

8. Moghissi ES, Korythkowski MT, DiNardo M, et al., American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control. Endocrine Practice 2009; 15(4):1-17.

Tight Glycemic Control Survey

For nearly a decade, hospitals have worked to establish glycemic control programs to better manage inpatient blood glucose, primarily in the intensive care unit.  Several randomized controlled trials, 1, 2, 3 and extensive anecdotal and observational data4, 5, 6 have demonstrated a consistent, direct relationship between hyperglycemia and increased complications and mortality.  This survey was conducted to determine the current state of glycemic control in U.S. hospitals.   A summary of the results will be posted when completed. Click Here to View the Survey

1. Van den Berghe G, Wouters P, Weekers F, et al., Intensive Insulin Therapy in Critically Ill Patients.  New England Journal of Medicine 2001; 345(19):1359-1367.

2. Furnary AP, Gao G, Grunkemeier GL, Wu Y, et al., Continuous Insulin Infusion Reduces Mortality in Patients With Diabetes Undergoing Coronary Artery Bypass Grafting.  Journal of Thoracic and Cardiovascular Surgery 2003; 12:1007-1021.

3. Van den Berghe G, Wilmer A, Hermans G et al, Intensive Insulin Therapy in the Medical ICU. New England Journal of Medicine 2006; 354(5):449-461.

4. Umpierrez GE, Isaacs SD, Bazargan N, You X et al.  Hyperglycemia: An Independent Marker of In-Hospital Mortality in Patients with Undiagnosed Diabetes.  Journal of Clinical Endocrinology and Metabolism 2002; 87(3):978-982.

5. Krinsley JS, Effect of an Intensive Glucose Management Protocol on the Mortality of Critically Ill Adult Patients.  Mayo Clinic Proceedings 2004; 79(8)992-1000.

6. Lacherade JD, Jabre P, Bastuji-Garin S, et al., Failure to Achieve Glycemic Control Despite Intensive Insulin Therapy in a Medical ICU: Incidence and Influence on ICU Mortality.  Intensive Care Medicine 2007; 33(5):814-21.

7. The NICE-SUGAR Investigators. Intensive versus conventional glucose control in critically ill patients. The New England Journal of Medicine. March 2009; 360(13):1283-1297.

8. Moghissi ES, Korythkowski MT, DiNardo M, et al., American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control. Endocrine Practice 2009; 15(4):1-17.

FDA Clears GlucoStabilizer Intravenous Insulin Dosing Software
 

CHARLOTTESVILLE, VA, October 17, 2007 – Medical Decisions Network (MDN) announces Food and Drug Administration 510(k) clearance for the company’s GlucoStabilizer IV Insulin Dosing Software. GlucoStabilizer software is used by hospital nurses to quickly and accurately calculate the dosage of intravenous insulin administered to patients with elevated levels of blood glucose, the simple form of sugar the body converts to energy for survival.

The CG-EGA is a Windows-based, statistical program designed for use by the diabetes technology industry in the evaluation of continuous glucose monitoring (CGM) devices.

The CG-EGA is a logical extension of the original error grid analysis (EGA), which was developed for assessing the clinical accuracy of patient-determined blood glucose values using either estimation or self-monitoring blood glucose systems. The CG-EGA is based upon the premise that information being generated by a monitoring system should be reliable enough to result in clinically accurate decision making by the user. Click Here to View a Demo of the CG-EGA

In November 2004, The Epsilon Group was acquired by Medical Automation Systems, Inc. (MAS). MAS is the leader in point-of-care informatics for hospitals and has placed it's RALS® data management technology in nearly 1,000 hospitals across the United States. The acquisition enables The Epsilon Group to provide MAS with the ability to offer customized post-marketing studies as well as enhanced, comprehensive services to it's existing customer base

FDA Clears GlucoStabilizer Intravenous Insulin Dosing Software

Epsilon Introduces Continuous Glucose - Error Grid Analysis (CG-EGA)